Vistagen Therapeutics (MEX:VTGN) Volatility: N/A% (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
16 GF Score
Price MXN10.65
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Volatility?

Vistagen Therapeutics MEX:VTGN 16 Volatility is N/A% as of Aug. 11, 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

Vistagen Therapeutics does not have enough data to calculate Volatility.

Vistagen Therapeutics  (MEX:VTGN) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Vistagen Therapeutics Volatility Related Terms

MEX:VTGN
16GF Score
Vistagen Therapeutics Inc MEX:VTGN
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics  (MEX:VTGN) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of N/A% mean?
Vistagen Therapeutics (MEX:VTGN) has a Volatility of N/A% as of Aug. 11, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Volatility too high?
Vistagen Therapeutics' current Volatility is N/A%. Overall, Vistagen Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Volatility compare to ASBP and CRIS?
Vistagen Therapeutics' Volatility of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Volatility is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current Volatility of N/A%. The current Volatility is N/A%. Vistagen Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current Volatility is N/A% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
16GF Score

Get the complete analysis for MEX:VTGN

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price